These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 23035247)

  • 1. A framework for identification of actionable cancer genome dependencies in small cell lung cancer.
    Sos ML; Dietlein F; Peifer M; Schöttle J; Balke-Want H; Müller C; Koker M; Richters A; Heynck S; Malchers F; Heuckmann JM; Seidel D; Eyers PA; Ullrich RT; Antonchick AP; Vintonyak VV; Schneider PM; Ninomiya T; Waldmann H; Büttner R; Rauh D; Heukamp LC; Thomas RK
    Proc Natl Acad Sci U S A; 2012 Oct; 109(42):17034-9. PubMed ID: 23035247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
    Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
    Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets.
    Krushkal J; Silvers T; Reinhold WC; Sonkin D; Vural S; Connelly J; Varma S; Meltzer PS; Kunkel M; Rapisarda A; Evans D; Pommier Y; Teicher BA
    Clin Epigenetics; 2020 Jun; 12(1):93. PubMed ID: 32586373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling.
    Li J; Fang B; Kinose F; Bai Y; Kim JY; Chen YA; Rix U; Koomen JM; Haura EB
    Mol Cancer Ther; 2016 Feb; 15(2):334-42. PubMed ID: 26772203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.
    Mollaoglu G; Guthrie MR; Böhm S; Brägelmann J; Can I; Ballieu PM; Marx A; George J; Heinen C; Chalishazar MD; Cheng H; Ireland AS; Denning KE; Mukhopadhyay A; Vahrenkamp JM; Berrett KC; Mosbruger TL; Wang J; Kohan JL; Salama ME; Witt BL; Peifer M; Thomas RK; Gertz J; Johnson JE; Gazdar AF; Wechsler-Reya RJ; Sos ML; Oliver TG
    Cancer Cell; 2017 Feb; 31(2):270-285. PubMed ID: 28089889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Family matters: How MYC family oncogenes impact small cell lung cancer.
    Brägelmann J; Böhm S; Guthrie MR; Mollaoglu G; Oliver TG; Sos ML
    Cell Cycle; 2017 Aug; 16(16):1489-1498. PubMed ID: 28737478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
    Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
    Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cells Lacking the
    Oser MG; Fonseca R; Chakraborty AA; Brough R; Spektor A; Jennings RB; Flaifel A; Novak JS; Gulati A; Buss E; Younger ST; McBrayer SK; Cowley GS; Bonal DM; Nguyen QD; Brulle-Soumare L; Taylor P; Cairo S; Ryan CJ; Pease EJ; Maratea K; Travers J; Root DE; Signoretti S; Pellman D; Ashton S; Lord CJ; Barry ST; Kaelin WG
    Cancer Discov; 2019 Feb; 9(2):230-247. PubMed ID: 30373918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
    Wang Y; Wu L; Yao Y; Lu G; Xu L; Zhou J
    Cancer Lett; 2018 Nov; 436():1-9. PubMed ID: 30118839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines.
    Sak A; Stuschke M; Groneberg M; Kübler D; Pöttgen C; Eberhardt WE
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):492-9. PubMed ID: 22381900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.
    Ramkumar K; Tanimoto A; Della Corte CM; Stewart CA; Wang Q; Shen L; Cardnell RJ; Wang J; Polanska UM; Andersen C; Saeh J; Pease JE; Travers J; Fabbri G; Gay CM; Urosevic J; Byers LA
    Clin Cancer Res; 2023 Aug; 29(16):3237-3249. PubMed ID: 37289191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromodomain and hedgehog pathway targets in small cell lung cancer.
    Kaur G; Reinhart RA; Monks A; Evans D; Morris J; Polley E; Teicher BA
    Cancer Lett; 2016 Feb; 371(2):225-39. PubMed ID: 26683772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
    PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.
    den Hollander J; Rimpi S; Doherty JR; Rudelius M; Buck A; Hoellein A; Kremer M; Graf N; Scheerer M; Hall MA; Goga A; von Bubnoff N; Duyster J; Peschel C; Cleveland JL; Nilsson JA; Keller U
    Blood; 2010 Sep; 116(9):1498-505. PubMed ID: 20519624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
    Krystal GW; Sulanke G; Litz J
    Mol Cancer Ther; 2002 Sep; 1(11):913-22. PubMed ID: 12481412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 orchestrates the response to BI-2536 and its combination with alisertib in MYC-driven small cell lung cancer.
    Zhang J; Liu X; Hou P; Lv Y; Li G; Cao G; Wang H; Lin W
    Cell Death Dis; 2024 Jul; 15(7):551. PubMed ID: 39085197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins.
    Chi YH; Yeh TK; Ke YY; Lin WH; Tsai CH; Wang WP; Chen YT; Su YC; Wang PC; Chen YF; Wu ZW; Yeh JY; Hung MC; Wu MH; Wang JY; Chen CP; Song JS; Shih C; Chen CT; Chang CP
    J Med Chem; 2021 Jun; 64(11):7312-7330. PubMed ID: 34009981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
    Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
    Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.
    Miura A; Sootome H; Fujita N; Suzuki T; Fukushima H; Mizuarai S; Masuko N; Ito K; Hashimoto A; Uto Y; Sugimoto T; Takahashi H; Mitsuya M; Hirai H
    Invest New Drugs; 2021 Jun; 39(3):724-735. PubMed ID: 33409897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.